SCHEMBL487883

SCHEMBL487883

CC(C)Cn1cnc2c(C(N)=O)nc3ccccc3c21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 7/20 0.68
PDE4D Q08499 2/20 0.68
LMNA P02545 1/20 0.68
POLB P06746 1/20 0.68
HRH2 P25021 1/20 0.68
ADRA1D P25100 1/20 0.68
HTR2A P28223 1/20 0.68
ADORA2A P29274 1/20 0.68
ADRA1A P35348 1/20 0.68
NUDT1 P36639 1/20 0.68
HTR2B P41595 1/20 0.68
KCNH2 Q12809 1/20 0.68
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
APAF1 O14727 1/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
TLR8 Q9NR97 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4540946 0.99 TLR7 (0.67) TLR7PDE4DLMNAPOLBHRH2
Glycine SCHEMBL3195843 0.94 TLR7 (0.61) TLR7PDE4DLMNAPOLBHRH2
Sarcosine SCHEMBL18477799 0.93 TLR7 (0.59) TLR7PDE4DLMNAPOLBHRH2
SCHEMBL18477815 0.93 TLR7 (0.59) TLR7PDE4DLMNAPOLBHRH2
Sarcosine SCHEMBL3191326 0.92 TLR7 (0.58) TLR7PDE4DLMNAPOLBHRH2
Imiquimod SCHEMBL5262205 0.83 TLR7 (0.88) TLR7PDE4DLMNAPOLBHRH2
SCHEMBL3176637 0.83 TLR7 (0.46) TLR7PDE4DLMNAPOLBHRH2
Hydrochloric Acid SCHEMBL3195855 0.83 TLR7 (0.58) TLR7PDE4DLMNAPOLBHRH2
SCHEMBL3192280 0.82 TLR7 (0.46) TLR7PDE4DLMNAPOLBHRH2
Hydrochloric Acid SCHEMBL18916713 0.82 TLR7 (0.46) TLR7PDE4DLMNAPOLBHRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106202-B2 Method for making 1-substituted 1H-imidazo [4,5-C] quinolin-4-amine compounds and intermediates therefor FERRER INTERNACIONAL, S.A. (ES) 2012-01-31 US claimed
EP-1879893-B1 METHOD FOR MAKING 1-SUBSTITUTED 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE COMPOUNDS AND INTERMEDIATES THEREFOR FERRER INT (ES) 2010-06-02 EP claimed
US-20090005566-A1 Method for Making 1-Substituted 1H-Imidazo [4,5-C] Quinolin-4-Amine Compounds and Intermediates Therefor FERRER INTERNACIONAL, S.A. (ES) 2009-01-01 US claimed
EP-3176169-A1 POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND RELATED COMPOUNDS WITH VERY HIGH SKIN PENETRATION RATES Yu, Chongxi (US) 2017-06-07 EP disclosed
US-9567329-B2 High penetration prodrug compositions of 1H-imidazo[4,5-c]quinolin-4-amines and 1H-imidazo[4,5-c]quinolin-4-amine-related compounds and uses thereof TECHFIELDS PHARMA CO., LTD. (CN) 2017-02-14 US disclosed
EP-2115140-B1 Positively charged water-soluble prodrugs of 1H-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates YU CHONGXI (US) 2016-11-30 EP disclosed
US-20130131100-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS AND USES THEREOF PREMIER RESEARCH INTERNATIONAL, LLC 2013-05-23 US disclosed
US-8349866-B2 High penetration prodrug compositions of 1H-imidazo[4,5-C]quinolin-4-amines and 1H-imidazo[4,5-C]quinolin-4-amine-related compounds PREMIER RESEARCH INTERNATIONAL, LLC 2013-01-08 US disclosed
US-8106202-B2 Method for making 1-substituted 1H-imidazo [4,5-C] quinolin-4-amine compounds and intermediates therefor FERRER INTERNACIONAL, S.A. (ES) 2012-01-31 US disclosed
EP-1879893-B1 METHOD FOR MAKING 1-SUBSTITUTED 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE COMPOUNDS AND INTERMEDIATES THEREFOR FERRER INT (ES) 2010-06-02 EP disclosed
US-20100021394-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS PREMIER RESEARCH INTERNATIONAL, LLC 2010-01-28 US disclosed
US-20050119294-A1 Preparation of 1H-imidazo [4,5-c] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates BIOGAL GYOGYSZERGYAR RT. 2005-06-02 US disclosed
US-20050101627-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4 amines via novel 1h-imidazo [4,5-C] quinolin-4-cyano and 1h-imidazo [4,5-C] quinolin-4-carboxamide intermediates TEVA PHARAMCEUTICAL INDUSTRIES LTD TO BIOGAL GYOGYSZERGYAR RT. 2005-05-12 US disclosed
US-20050101627-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4 amines via novel 1h-imidazo [4,5-C] quinolin-4-cyano and 1h-imidazo [4,5-C] quinolin-4-carboxamide intermediates TEVA PHARAMCEUTICAL INDUSTRIES LTD TO BIOGAL GYOGYSZERGYAR RT. 2005-05-12 US disclosed
US-6841678-B2 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates BIOGAL GYOGYSZERGYAR RT. (HU) 2005-01-11 US disclosed
US-6841678-B2 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates BIOGAL GYOGYSZERGYAR RT. (HU) 2005-01-11 US disclosed
US-20040063743-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) 2004-04-01 US disclosed
US-20040063743-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG (HU) 2004-04-01 US disclosed
WO-2004011462-A1 PREPARATION OF 1H-IMIDAZO [4,5-C] QUINOLIN-4-AMINES VIA NOVEL 1H-IMIDAZO [4,5-C] QUINOLIN-4-CYANO AND 1H-IMIDAZO [4,5-C] QUINOLIN-4-CARBOXAMIDE INTERMEDIATES BIOGAL GYOGYSZERGYAR RT. (HU) 2004-02-05 WO disclosed
WO-2004011462-A1 PREPARATION OF 1H-IMIDAZO [4,5-C] QUINOLIN-4-AMINES VIA NOVEL 1H-IMIDAZO [4,5-C] QUINOLIN-4-CYANO AND 1H-IMIDAZO [4,5-C] QUINOLIN-4-CARBOXAMIDE INTERMEDIATES BIOGAL GYOGYSZERGYAR RT. (HU) 2004-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101627-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4 amines via novel 1h-imidazo [4,5-C] quinolin-4-cyano and 1h-imidazo [4,5-C] quinolin-4-carboxamide intermediates KDM4C, P2RX4, IL4 TLR7 4/4885PDE4D 578/4885LMNA 430/4885
US-20130131100-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS AND USES THEREOF HRH4, SLC7A1, ABCG2 TLR7 1432/4885PDE4D 747/4885LMNA 1869/4885
US-20100021394-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS SLC7A1, HRH4, CYP3A4 TLR7 1413/4885PDE4D 797/4885LMNA 1935/4885
US-20040063743-A1 Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates IL4, MCM4, CUL4A TLR7 13/4885PDE4D 498/4885LMNA 632/4885
US-20050119294-A1 Preparation of 1H-imidazo [4,5-c] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates KDM4C, IFNAR1, P2RX4 TLR7 8/4885PDE4D 559/4885LMNA 539/4885
US-20090005566-A1 Method for Making 1-Substituted 1H-Imidazo [4,5-C] Quinolin-4-Amine Compounds and Intermediates Therefor CYP4B1, QARS1, CYP4F11 TLR7 1849/4885PDE4D 671/4885LMNA 2306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.